This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Meridian Bioscience stock | $18.05

Own Meridian Bioscience stock in just a few minutes.

Posted

Fact checked

Meridian Bioscience, Inc is a diagnostics & research business based in the US. Meridian Bioscience shares (VIVO) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Meridian Bioscience

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Meridian Bioscience. Find the stock by name or ticker symbol: VIVO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Meridian Bioscience reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$18.05, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Meridian Bioscience, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Meridian Bioscience. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Meridian Bioscience share price

Use our graph to track the performance of VIVO stocks over time.

Meridian Bioscience shares at a glance

Information last updated 2020-12-01.
Latest market close USD$18.05
52-week range USD$5.51 - USD$26.58
50-day moving average USD$18.1983
200-day moving average USD$18.4995
Wall St. target price USD$25.58
PE ratio 17.7196
Dividend yield N/A (1.27%)
Earnings per share (TTM) USD$1.07

Buy Meridian Bioscience shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Meridian Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Meridian Bioscience price performance over time

Historical closes compared with the close of $18.05 from 2020-11-16

1 week (2020-11-25) 1.63%
1 month (2020-11-06) -3.37%
3 months (2020-09-04) 31.75%
6 months (2020-06-05) 14.28%
1 year (2019-12-05) 98.57%
2 years (2018-12-04) -3.53%
3 years (2017-12-05) 21.96%
5 years (2015-12-04) -7.91%

Is Meridian Bioscience under- or over-valued?

Valuing Meridian Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Meridian Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Meridian Bioscience's P/E ratio

Meridian Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Meridian Bioscience shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Meridian Bioscience's PEG ratio

Meridian Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.33. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Meridian Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Meridian Bioscience's EBITDA

Meridian Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$74.2 million.

The EBITDA is a measure of a Meridian Bioscience's overall financial performance and is widely used to measure a its profitability.

Meridian Bioscience financials

Revenue TTM USD$253.7 million
Operating margin TTM 24.32%
Gross profit TTM USD$156.2 million
Return on assets TTM 9.64%
Return on equity TTM 21.77%
Profit margin 18.21%
Book value $5.447
Market capitalisation USD$816.7 million

TTM: trailing 12 months

Shorting Meridian Bioscience shares

There are currently 3.4 million Meridian Bioscience shares held short by investors – that's known as Meridian Bioscience's "short interest". This figure is 0.5% up from 3.4 million last month.

There are a few different ways that this level of interest in shorting Meridian Bioscience shares can be evaluated.

Meridian Bioscience's "short interest ratio" (SIR)

Meridian Bioscience's "short interest ratio" (SIR) is the quantity of Meridian Bioscience shares currently shorted divided by the average quantity of Meridian Bioscience shares traded daily (recently around 559261.95121951). Meridian Bioscience's SIR currently stands at 6.15. In other words for every 100,000 Meridian Bioscience shares traded daily on the market, roughly 6150 shares are currently held short.

However Meridian Bioscience's short interest can also be evaluated against the total number of Meridian Bioscience shares, or, against the total number of tradable Meridian Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Meridian Bioscience's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Meridian Bioscience shares in existence, roughly 80 shares are currently held short) or 0.1073% of the tradable shares (for every 100,000 tradable Meridian Bioscience shares, roughly 107 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Meridian Bioscience.

Find out more about how you can short Meridian Bioscience stock.

Meridian Bioscience share dividends

We're not expecting Meridian Bioscience to pay a dividend over the next 12 months.

Have Meridian Bioscience's shares ever split?

Meridian Bioscience's shares were split on a 3:2 basis on 14 May 2007. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Meridian Bioscience shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Meridian Bioscience shares which in turn could have impacted Meridian Bioscience's share price.

Meridian Bioscience share price volatility

Over the last 12 months, Meridian Bioscience's shares have ranged in value from as little as $5.51 up to $26.58. A popular way to gauge a stock's volatility is its "beta".

VIVO.US volatility(beta: 0.55)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Meridian Bioscience's is 0.5502. This would suggest that Meridian Bioscience's shares are less volatile than average (for this exchange).

Meridian Bioscience overview

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site